BioCentury
ARTICLE | Company News

Taiwan Liposome, Novartis sales and marketing update

January 6, 2014 8:00 AM UTC

On Dec. 18, 2013, Taiwan Liposome granted Novartis' Sandoz AG generics unit rights to commercialize AmBiL amphotericin B - a generic version of antifungal drug AmBisome from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) - in the U.S. and EU. Amphotericin B is a unilamellar liposomal formulation of amphotericin B. Sandoz directed questions to Taiwan Liposome, which declined to disclose financial details but said the deal includes milestone payments and profit sharing. Taiwan Liposome said Sandoz hopes to launch the product in the EU in 2015 and in the U.S. the following year. The company said it has finished preparing the ANDA submission dossier, and Sandoz will submit regulatory applications in Europe in early 2014. ...